share_log

科濟藥業-B：自願公告 - 正在進行的賽愷澤和CT071的研究的摘要將在即將舉行的2024年EHA年會分別進行口頭報告和壁報展示

CARSGEN-B: VOLUNTARY ANNOUNCEMENT - ABSTRACTS FROM THE ONGOING STUDIES OF ZEVORCABTAGENE AUTOLEUCEL AND CT071 ARE TO BE PRESENTED AS AN ORAL PRESENTATION AND A POSTER PRESENTATION, RESPECTIVELY, AT THE UPCOMING EHA 2024

Hong Kong Stock Exchange ·  Apr 30 08:00
Summary by Futu AI
科濟藥業-B（股份代號：2171）宣布，其兩款自體CAR-T細胞治療產品賽愷澤®和CT071的研究摘要將在2024年歐洲血液學協會（EHA）年會上進行口頭報告和壁報展示。賽愷澤®是針對BCMA的CAR-T產品，已於2024年2月23日獲得國家藥品監督管理局批准上市，用於治療經過至少3線治療後進展的復發或難治性多發性骨髓瘤成人患者。此外，科濟藥業正在北美進行1b/2期臨床試驗，評估賽愷澤®治療相同疾病的安全性及療效。CT071則是針對GPRC5D的CAR-T細胞治療候選產品，目前在中國進行臨床試驗，旨在評估其治療復發或難治性多發性骨髓瘤及漿細胞白血病的安全性和有效性。科濟藥業專注於血液惡性腫瘤和實體瘤的CAR-T細胞療法，致力於成為全球生物製藥的領導者。
科濟藥業-B（股份代號：2171）宣布，其兩款自體CAR-T細胞治療產品賽愷澤®和CT071的研究摘要將在2024年歐洲血液學協會（EHA）年會上進行口頭報告和壁報展示。賽愷澤®是針對BCMA的CAR-T產品，已於2024年2月23日獲得國家藥品監督管理局批准上市，用於治療經過至少3線治療後進展的復發或難治性多發性骨髓瘤成人患者。此外，科濟藥業正在北美進行1b/2期臨床試驗，評估賽愷澤®治療相同疾病的安全性及療效。CT071則是針對GPRC5D的CAR-T細胞治療候選產品，目前在中國進行臨床試驗，旨在評估其治療復發或難治性多發性骨髓瘤及漿細胞白血病的安全性和有效性。科濟藥業專注於血液惡性腫瘤和實體瘤的CAR-T細胞療法，致力於成為全球生物製藥的領導者。
Kozin Pharmaceutical-B (stock code: 2171) announced that the research summary of its two autologous CAR-T cell therapy products, Saikaize® and CT071, will be presented at the European Society of Hematology (EHA) Annual Meeting in 2024. Saikaize® is a CAR-T product for BCMA that was approved by the National Drug Administration on February 23, 2024 for the treatment of relapsed or incurable multiple myeloma adult patients who have undergone at least 3 lines of treatment. In addition, Kozai Pharmaceuticals is conducting a Phase 1b/2 clinical trial in North America to evaluate the safety and efficacy of Saikaze® for the treatment of the same disease. CT071, a candidate for CAR-T cell therapy for GPRC5D, is currently undergoing clinical trials in China to evaluate the safety and efficacy of its treatment of relapsed or incurable multiple myeloma and squamous cell leukemia. Focusing on CAR-T cell therapy for malignant tumors and solid tumors of the blood, Kozin Pharmaceuticals is committed to becoming a global leader in biopharmaceuticals.
Kozin Pharmaceutical-B (stock code: 2171) announced that the research summary of its two autologous CAR-T cell therapy products, Saikaize® and CT071, will be presented at the European Society of Hematology (EHA) Annual Meeting in 2024. Saikaize® is a CAR-T product for BCMA that was approved by the National Drug Administration on February 23, 2024 for the treatment of relapsed or incurable multiple myeloma adult patients who have undergone at least 3 lines of treatment. In addition, Kozai Pharmaceuticals is conducting a Phase 1b/2 clinical trial in North America to evaluate the safety and efficacy of Saikaze® for the treatment of the same disease. CT071, a candidate for CAR-T cell therapy for GPRC5D, is currently undergoing clinical trials in China to evaluate the safety and efficacy of its treatment of relapsed or incurable multiple myeloma and squamous cell leukemia. Focusing on CAR-T cell therapy for malignant tumors and solid tumors of the blood, Kozin Pharmaceuticals is committed to becoming a global leader in biopharmaceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.